Alba Herrero-Morant, Carmen Álvarez-Reguera, José L Martín-Varillas, Vanesa Calvo-Río, Alfonso Casado, Diana Prieto-Peña, Belén Atienza-Mateo, Olga Maiz-Alonso, Ana Blanco, Esther Vicente, Íñigo Rúa-Figueroa, Laura Cáceres-Martin, José L García-Serrano, José Luis Callejas-Rubio, Norberto Ortego-Centeno, Javier Narváez, Susana Romero-Yuste, Julio Sánchez, Paula Estrada, Rosalía Demetrio-Pablo, David Martínez-López, Santos Castañeda, José L Hernández, Miguel Á González-Gay, Ricardo Blanco
We aimed to assess the efficacy of biologic therapy in refractory non-Multiple Sclerosis (MS) Optic Neuritis (ON), a condition more infrequent, chronic and severe than MS ON. This was an open-label multicenter study of patients with non-MS ON refractory to systemic corticosteroids and at least one conventional immunosuppressive drug. The main outcomes were Best Corrected Visual Acuity (BCVA) and both Macular Thickness (MT) and Retinal Nerve Fiber Layer (RNFL) using Optical Coherence Tomography (OCT). These outcome variables were assessed at baseline, 1 week, and 1, 3, 6 and 12 months after biologic therapy initiation...
August 11, 2020: Journal of Clinical Medicine